BioArctic AB (BIOA_B) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bioarctic Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.875 -- 00:00:05.523 Good morning and welcome to Biotic's presentation for the fourth quarter and for the 00:00:05.523 -- 00:00:08.349 full year of 2025. It 00:00:08.349 -- 00:00:11.394 has been a fantastic year for Biotic. 00:00:11.394 -- 00:00:13.017 In 2025 00:00:13.017 -- 00:00:17.966 we entered into a new era that we call the growth era. 00:00:17.966 -- 00:00:23.036 And we can conclude that we have a transformative year behind us with record 00:00:23.036 -- 00:00:25.310 financial results. 00:00:25.310 -- 00:00:30.720 We are making our science accessible to more and more patients than ever before. 00:00:30.720 -- 00:00:34.807 And I think it's great and reassuring to see that more and more patients are getting 00:00:34.807 -- 00:00:36.911 access to Lecambi. 00:00:36.911 -- 00:00:42.160 We are accelerating our innovations. Our portfolio is progressing really well and 00:00:42.160 -- 00:00:47.690 has been further expanded. And our brain transporter technology is further evolving 00:00:47.690 -- 00:00:50.171 with new innovations. 00:00:50.352 -- 00:00:53.419 We have increased focus on business development. 00:00:53.419 -- 00:00:58.491 We are broadening our collaborations and utilizing our brain transporter technology. 00:00:58.491 -- 00:01:01.839 And we'll talk more about all this in today's presentation. 00:01:01.839 -- 00:01:04.165 Next slide, please. 00:01:04.165 -- 00:01:08.094 Biotic is listed at Nasdaq Stockholm large cap, and this is our disclaimer. 00:01:08.094 -- 00:01:10.595 Next slide, please. 00:01:10.737 -- 00:01:13.641 I'm Gunilla Åsvall, and I'm the CEO of Biotic. 00:01:13.641 -- 00:01:18.767 And I will share today's presentation with our CFO, Anders Martin Lööf, and our chief 00:01:18.767 -- 00:01:24.655 R&D officer, Johanna Felting, an...